Holen Sie sich die Stockscreener-App
6.115
1.24%
0.075
Handel nachbörslich:
6.15
0.035
+0.57%
Schlusskurs vom Vortag:
$6.04
Offen:
$6.04
24-Stunden-Volumen:
74,329
Relative Volume:
1.11
Marktkapitalisierung:
$175.28M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-8.73%
1M Leistung:
-7.77%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$5.844
$6.15
1-Wochen-Bereich:
$5.82
$6.66
52-Wochen-Spanne:
$2.33
$8.51
Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile
Firmenname
Insight Molecular Diagnostics Inc
Sektor
Branche
Telefon
949-409-7600
Adresse
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE
Vergleichen Sie IMDX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMDX
Insight Molecular Diagnostics Inc
|
6.115 | 173.13M | 0 | 0 | 0 | 0.00 |
|
TMO
Thermo Fisher Scientific Inc
|
586.07 | 220.72B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
226.98 | 160.62B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
752.14 | 57.96B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
153.60 | 42.88B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
228.18 | 38.30B | 15.90B | 1.28B | 2.21B | 7.2842 |
Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-28 | Eingeleitet | Lake Street | Buy |
| 2022-05-24 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-03-14 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2022-01-07 | Eingeleitet | Stephens | Overweight |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-03-17 | Fortgesetzt | Needham | Buy |
| 2021-01-07 | Hochstufung | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-16 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-11-30 | Eingeleitet | BTIG Research | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-07-30 | Bestätigt | The Benchmark Company | Speculative Buy |
| 2020-07-01 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-06-30 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2020-06-02 | Eingeleitet | Needham | Buy |
| 2019-02-13 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-01-29 | Hochstufung | Janney | Neutral → Buy |
| 2018-12-19 | Fortgesetzt | Lake Street | Buy |
Alle ansehen
Insight Molecular Diagnostics Inc Aktie (IMDX) Neueste Nachrichten
Insight Molecular Diagnostics (IMDX) Price Target Increased by 29.23% to 7.14 - MSN
Will Insight Molecular Diagnostics Inc. (7OC0) stock remain on Wall Street radarJuly 2025 Weekly Recap & Fast Entry High Yield Stock Tips - newser.com
Will Insight Molecular Diagnostics Inc. (7OC0) stock gain from green policiesQuarterly Market Summary & Expert Approved Momentum Ideas - newser.com
Can Insight Molecular Diagnostics Inc. (7OC0) stock sustain institutional flowsJuly 2025 Breakouts & Verified High Yield Trade Plans - newser.com
Why Insight Molecular Diagnostics Inc. (7OC0) stock stays resilient2025 Geopolitical Influence & Weekly Top Performers Watchlists - newser.com
Published on: 2025-11-19 17:04:49 - newser.com
Published on: 2025-11-19 13:52:26 - newser.com
Published on: 2025-11-19 13:17:14 - newser.com
Is Insight Molecular Diagnostics Inc. (7OC0) stock worth holding before Fed meetingMarket Volume Report & Capital Efficient Trade Techniques - newser.com
How Insight Molecular Diagnostics Inc. (7OC0) stock trades under stagflation2025 Sector Review & Precise Swing Trade Alerts - newser.com
Is Insight Molecular Diagnostics Inc. (7OC0) stock a top pick for value investorsQuarterly Market Review & Free High Return Stock Watch Alerts - newser.com
This Biotech Stock Is Up 158% in a Year. What’s Driving It Higher? - MSN
Insight Molecular Diagnostics Inc.Common Stock (NQ: IMDX - Markets Financial Content
Insight Molecular Diagnostics Advances Kidney Transplant Monitoring with New Study - MSN
Insight Molecular Diagnostics: GraftAssureDX FDA Submission Warrants Hold Rating (IMDX) - Seeking Alpha
Finanzdaten der Insight Molecular Diagnostics Inc-Aktie (IMDX)
Es liegen keine Finanzdaten für Insight Molecular Diagnostics Inc (IMDX) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.35%
1.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):